Elimination of Senescent Cells Approach for treatment of COPD

Projektinformationen

ESCAPE_COPD

ID Finanzhilfevereinbarung: 727218

DOI 10.3030/727218

Projekt abgeschlossen

EK-Unterschriftsdatum 5 April 2017

Startdatum 1 Mai 2017

Enddatum 31 Oktober 2018

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten € 150 000,00

EU-Beitrag € 150 000,00

Koordiniert durch

WEIZMANN INSTITUTE OF SCIENCE
Israel

Ziel

Chronic Obstructive Pulmonary Disease (COPD) is estimated to affect up to 600 million people worldwide and by 2020 it will become the third most frequent cause of death. In Europe alone, COPD affects up to 10% of people (i.e. more people than breast cancer and diabetes) and it takes the life of around 300,000 Europeans each year. Current therapies are associated with a variety of side effects some of which can be acute and even life threatening. Moreover, none of the existing medications for COPD has been shown conclusively to modify the long-term decline in lung function thus, COPD remains a disease with a significant unmet medical need.
Our approach is focusing on the pharmacological elimination of senescent cells (i.e. cells that have stopped dividing, but do affect their microenvironment) which accumulate in tissues with age and contribute to multiple age-related diseases, including COPD. In particular, we recently discovered that with the use of a particular molecule, we could efficiently target the molecular mechanisms that are responsible for the viability of senescent cells, leading to specific elimination of these cells from tissues. In turn, the goal of the PoC project is two-fold. (1) The first goal is to establish the technical feasibility of our idea by testing the effect of the identified molecule on the disease development and progression using the COPD mouse model we developed. (2) The second goal is to establish the business feasibility of our revolutionary approach by taking the necessary steps towards its commercialization, focusing on the creation of strategic alliances with key private sector companies.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › clinical medicine › endocrinology › diabetes
• medical and health sciences › clinical medicine › oncology › breast cancer

Programm/Programme

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Thema/Themen

• ERC-PoC-2016 - ERC-Proof of Concept-2016

Aufforderung zur Vorschlagseinreichung

ERC-2016-PoC

Finanzierungsplan

ERC-POC - Proof of Concept Grant

Gastgebende Einrichtung

WEIZMANN INSTITUTE OF SCIENCE

• Netto-EU-Beitrag: € 150 000,00
• Adresse: HERZL STREET 234 ; 7610001 Rehovot ; Israel
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: € 150 000,00

Begünstigte (1)

WEIZMANN INSTITUTE OF SCIENCE

Israel

• Netto-EU-Beitrag: € 150 000,00
• Adresse: HERZL STREET 234 ; 7610001 Rehovot
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: € 150 000,00